Cancer centre deploys Biograph mCT hybrid PET-CT system from Siemens Healthcare
Technology that would streamline workflow and keep dose to the most-appropriate level was important to the Paul Strickland Scanner Centre in its selection of a new PET-CT system and it has opted for a Biograph mCT hybrid PET-CT system from Siemens Healthcare.
Paul Strickland Scanner Centre is an independent medical charity based at Mount Vernon Hospital in London delivering specialist cancer care. It was one of the first in the UK to offer PET imaging, and now has a total of four Siemens imaging systems offering non-invasive diagnostic imaging to patients.
The Biograph mCT is a hybrid PET-CT system that utilises Combined Applications to Reduce Exposure (CARE), optimising image quality at the right dose level. Combined with Fully Assisting Scanner Technologies (FAST), which simplifies and automates previously time-consuming and complex procedures, the Biograph mCT is able to reduce dose and increase patient throughput.
Patient comfort is expected to be further enhanced with the system’s 78cm bore, short tunnel and 227kg table capacity, designed to provide greater flexibility, maximise the centre’s patient base, as well as provide greater accessibility for difficult to image patients.
“As a charity and one of the first centres in the UK to deliver PET scans to NHS district general hospitals, it is our aim to provide the community with the latest and most-efficient imaging systems. Patient comfort as well as confident diagnoses is our priority,” states Margaret Sullivan, chief executive of the Paul Strickland Scanner Centre.
“The Biograph mCT went through a rigorous clinician-led selection process and the decision was that it would be the best option suited to increasing patient throughput at the centre and helping to reduce the time between a patient’s diagnosis and development of their care management plan.”
“In addition to oncology, we are using the system for a small amount of memory loss imaging and hope to increase Alzheimer’s imaging in line with the recent G8 dementia summit announcement that leading nations have committed to developing treatments for dementia by 2025,” added Dr Anthony Chambers, consultant radiologist.
“PET-CT is recommended as a method of diagnosing Alzheimer’s by both the Intercollegiate Standing Committee 2013 and referenced in NICE guidelines on dementia, so we feel there will be a growing appetite for the use of FDG PET for specialist Alzheimer’s imaging.”